Please login to the form below

Not currently logged in
Email:
Password:

Merck melanoma drug approved

The US Food and Drug Administration has granted marketing approval to Merck's Sylatron (peginterferon alfa-2b) melanoma treatment

The US Food and Drug Administration (FDA) has granted marketing approval to Merck's Sylatron (peginterferon alfa-2b) melanoma treatment.

The drug, which is injected subcutaneously, is indicated for the adjuvant treatment of node-positive melanoma. Specifically, it has been cleared for use within 84 days of definitive surgical resection including complete lymphadenectomy for the treatment of melanoma with microscopic or gross nodal involvement. Patients can self-inject the drug once a week, Merck noted.

The approval was based on a single, open-label trial of 1,256 patients who had had surgery and were randomised to receive either Sylatron or observation for five years.

The primary efficacy endpoint was relapse-free survival, which had an estimated median time of 34.8 months in the treatment group and 25.5 months in the observation-only group. There was no difference in overall survival between the Sylatron and the observation arms.

The drug was developed by Schering-Plough and became part of Merck's pipeline when the two companies merged.

Sylatron is the second significant new drug for melanoma to win FDA approval in recent weeks. Last month, the FDA approved Bristol-Myers Squibb's Yervoy (ipilimumab) for the treatment of unresectable or metastatic melanoma, noting that the therapy demonstrates a 'significant improvement' in overall survival for patients whose skin cancer cannot be treated with surgery or has spread to other organs.

12th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics